



EDUCATIONAL FUND

**The My PrEP Study:
Lessons learnt from a pilot
demonstration project and
recommendations for scale up**


Iskandar Azwa

Infectious Diseases Unit, Faculty of Medicine
University of Malaya

Outline

- Background
- PrEP Timelines
- Results of the My PrEP study
- Lessons Learnt
- Considerations for scale Up
- Next Steps

Trend of HIV infection by Mode of Transmission (2000-2018)



Global AIDS Monitoring Report; Malaysia (2020)


Epidemiology Profile of Key Populations

Target Group	Estimated Population Size	HIV Prevalence* (2012)	HIV Prevalence* (2014)	HIV Prevalence* (2017)
People Who Inject Drugs (PWID)	75,000	18.9%	16.3%	13.4%
Female Sex Workers (FSW)	22,000	4.2%	7.3 %	6.3%
Transgender (TG)	15,000	4.8%	5.6 %	10.9%
Men who have Sex with Men (MSM)	220,000	7.1%	8.9 %	21.6%

¹ Ministry of Health Malaysia, Size Estimation of Key Populations Malaysia, 2018

* Results from the Integrated Bio-Behavioural Surveillance (IBBS) 2012 , 2014 in NSPEA 2016-2030, 2017

HIV prevalence among MSM, National and Kuala Lumpur, Malaysia integrated behavioral and biological surveillance, 2009-2017



Source: Kanter et al, 2011; IBBS, Ministry of Health, 2017

PrEP Timelines in Malaysia

Timeline	PrEP Initiative	Lead partner organization(s)
Aug 2015	Inclusion of PrEP in National Strategic Plan (NSP) to End AIDS (2016-2030)	MOH
Sept 2015	Regional PrEP Consultation (PrEPARING Asia), Bangkok	Led by APCOM
March 2016	Online PrEP Survey in MSM	International HIV Alliance
May 2016	National PrEP Consultation	MOH, WHO, UNAIDS, International HIV Alliance, APCOM (Global Fund)
May 2016	Formation of PrEP Working Group	
Sept 2016	Completion of National PrEP and nPEP guidelines	MASHM Out of pocket PrEP

PrEP Timelines - Cont

Timeline	PrEP Initiative	Lead partner organization(s)
Jan 2017	HIV Connect	MASHM, MAC, MAF
Jan 2017	1 st Asia Pacific PrEP Implementation Meeting, Bangkok	USAID, PEPFAR, FHI 360, TRC ARC
Dec 2017	Price reduction of generic TDF/FTC (generic competition)	Cipla, Hetero, Medispec
March 2018	Pilot multi-site PrEP demonstration project in MSM	UNAIDS/WHO/GF
July 2018	2 nd National PrEP Consultation on PrEP	CERIA, WHO
Jan 2019	HIV PrEP Locator	WHO, CERIA
Sept 2020	Community-led PrEP service delivery collaboration with FRHAM	MAC/AFAO (SKPA)

1st National Consultation on PrEP

- 2 day multi-sectorial consultation in May 2016
- Involved community members, CBOs, MOH, Pharma reps, ID physicians, researchers, primary care doctors, APCOM, WHO, UNAIDS, HIV Alliance
- MOH supportive of PrEP as an additional HIV preventive tool
 - Recommended more operational research and a pilot demonstration project to study the feasibility of PrEP implementation in key populations through a number of service delivery models using client paid PrEP
 - Emphasized non-MOH settings – e.g. university hospitals/private sector
 - MASHM to work with MAC to develop national PrEP and nPEP guidelines and training modules on PrEP targeting community friendly primary care public and private clinics

Key Findings: Willingness to use PrEP

- Relative risks & Perception of PrEP

- Most had low risk perception and felt that their frequency of condom use or being in a

- Bourne A et al. *Journal of the International AIDS Society* 2017, 20:21899
<http://www.jiasociety.org/index.php/jias/article/view/21899> | <http://dx.doi.org/10.7448/IAS.20.1.21899>



Research article

Willingness to use pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men (MSM) in Malaysia: findings from a qualitative study

- As:

- Adam Bourne^{1,2§}, Matteo Cassolato³, Clayton Koh Thuan Wei⁴, Bangyuan Wang³, Joselyn Pang⁵, Sin How Lim⁶, Iskandar Azwa⁷, Ilias Yee⁴ and Gitau Mburu⁸

[§]Corresponding author: Adam Bourne, Australian Research Centre in Sex, Health & Society, La Trobe University, 215 Franklin Street, Melbourne 3000, Australia. (A.bourne@latrobe.edu.au)


above that

al barrier
barriers in

health
as promiscuous

Accessing PrEP Service Preference

Where clients prefer to access PrEP services



Lim et al. Willingness to use Pre-exposure prophylaxis for HIV prevention among men who have sex with men in Malaysia, *PLOS-ONE* 2017

The My PrEP Study



Eligible participants will be given free PrEP for a year!

UMMC
The Red Clinic
CHCC Sentul

Interested? Questions?

WhatsApp UMMC: +6016 622 7919/ummcprep@gmail.com
The Red Clinic: +6019 2835550/ezra.ceria@gmail.com
CHCC Sentul: +6018 2763530/mishaanraman7@hotmail.com

If you think you might know someone who would need this or might be interested to be part of this study, please pass the message around (discreetly!)

PrEP STUDY FOR MSM

- Pilot demonstration project
- Funded by UNAIDS/WHO/Global Fund
- Partnered with Malaysian AIDS Council
- 150 HIV negative MSM at high risk of HIV infection over 12 months
- Free Generic Truvada based PrEP donated by Medispec & Cipla
- Across 3 sites:
 - University Malaya Medical Centre
 - Private clinic (Red Clinic)
 - Community Based Organization (Community Health Care Clinic, PTF)

Objective of My PrEP Study

- To evaluate retention, adherence, risk behavior, side-effects, STI and HIV breakthrough infections among MSM taking HIV PrEP
- To document delivery of HIV PrEP services to inform national policy, expansion and scale-up

Methods

Population

- Self-selected sample of 150 HIV uninfected MSM at three different service delivery sites in Klang Valley

Eligibility

Inclusion criteria

- Demographic: ≥ 18 years, male sex, Malaysian, living in Klang Valley for the next 12 months
- Sexual Risk Behaviour: Substantial risk for HIV infection
 - Hx of UAI with at least 1 male partner of unknown or HIV positive status
 - Hx of anogenital STI
 - Hx of recreational drug use for sex or transactional sex
 - Used or requested PEP

Exclusion criteria

- Acute or established HIV infection
- Creatinine clearance <60mL/min
- Adverse health conditions

Intervention


- Single daily oral dose of generically manufactured tenofovir/emtricitabine (Truvada®)

Study Procedures

Procedure	Baseline	Month 1	Month 3	Month 6	Month 9	Month 12
Rapid HIV Ag/Ab	X	X	X	X	X	X
HIV POC VL	X					
Creatinine	X	X		X		X
Rectal CT/NG	X			X		X
RPR/TPHA	X			X		X
HBsAg/Ab	X					
HCV-Ab	X					X
Questionnaire	X		X	X	X	X
Diary (weekly)	X	X	X	X	X	X
Drug dispensing	X	X	X	X	X	X
Pill count		X	X	X	X	X


Results

Study Design



Socio-demographic characteristics	
<i>Ethnicity</i>	n (%)
Chinese	85 (56.6)
Indian	12 (8.0)
Malay	44 (29.3)
Other	9 (6.0)
<i>Age group (years)</i>	
18 – 25	31 (20.7)
26 – 35	83 (55.3)
36 and over	36 (24.0)
<i>Education</i>	
High school	15 (10.0)
Diploma/degree	116 (77.3)
Post-graduate	19 (12.7)
<i>Employment status</i>	
Employed	122 (84.0)
Unemployed	24 (16.0)


Existing HIV risk factors* prior to enrollment




*Multiple risk factors possible

Existing HIV risk factors prior to enrollment


Number of HIV risk factors



Retention





Self-reported weekly PrEP adherence from diaries*



*Based on 5492 (73%) out of 7569 diaries expected throughout the course of the project

Sexual risk behaviour




Self-reported medical conditions during the first month after initiating PrEP

Condition*	n (%)
Diarrhea	27 (18.2)
Nausea	24 (16.2)
Decreased appetite	10 (6.8)
Dizziness/headache	16 (10.8)
Fever	6 (4.1)
Abdominal cramping	7 (4.7)
Flatulence	23 (15.5)
Sore throat	17 (11.5)

*More than one condition possible

Kidney Function Monitoring




Timeline	Mean	Range
Baseline	102.41ml/min/1.73 ²	60 - 132
Month 1	99.15ml/min/1.73 ²	51 - 129
Month 6	100.89ml/min/1.73 ²	60 - 131
Month 12	97.26ml/min/1.73 ²	59 - 133

Kidney function

- - Participant 040
 - Baseline eGFR = 60
 - Month 1 eGFR = 51 – 2 weeks after PrEP start, on creatine supplement, used methamphetamine. PrEP stopped and repeated eGFR after 2 weeks, remains < 60, off PrEP for 4 weeks. eGFR normalized and PrEP was restarted
 - Month 6 eGFR = 60
 - Month 12 eGFR = 60
- - Participant 076
 - Baseline eGFR: 70
 - Month 1 eGFR: 68
 - Month 6 eGFR: 71
 - Month 12 eGFR: 59 – Started creatine supplement 1 month prior, used methamphetamine. PrEP stopped for 2 weeks along with creatine supplement. Repeated eGFR after 2 weeks. Normalized and restarted PrEP

Sexually Transmitted Infections and HIV



Chemsex (aHR 1.46 (95% CI 1.03- 2.08) (p=0.036) and receptive AI (aHR 1.55 (95% CI 1.04- 2.30) (p=0.03) were significant predictors of STI positivity on multivariate analyses

Summary

- A sample of 150 MSM was successfully enrolled at three different PrEP service delivery sites in Klang Valley
- Men were in majority Chinese, young, well educated, employed and at very high risk for HIV infection
- Project retention and drug adherence were high (>90%), exceeding international standards
- Only minor changes in sexual risk behaviors were observed
- Some self-reported medical conditions following PrEP initiation seem to be elevated compared to one would expect in every-day life
- Decreases in kidney function below the eGFR threshold (<60) were associated with use of creatine supplements
- There were high rate of asymptomatic STIs at baseline, which preceded the initiation of PrEP

Lessons Learnt from CBO based PrEP delivery services (CHCC, PTF)



Client centred care

“Know the market as they are the market”

Trusted by key populations

First site that completed the enrolment in My PrEP study

More flexible opening hours

High retention rate

Limitation of resources - funding, laboratory support

Lack of recognition and certification of CBO staff as potential PrEP providers

Medico-legal issues around de-medicalization of PrEP

Training capacity

Cost

Lessons learnt and recommendations from My PrEP demonstration project (1)

- ***PrEP is a powerful biochemical HIV prevention strategy*** – no HIV infections reported in the cohort
- ***Messaging of “safer sex” in the era of PrEP needs to change to reduce stigma***
 - It is likely that with the perceived HIV protection offered by PrEP, rates of condomless sex are likely to increase over time.
 - The messaging of "safe sex" in the era of PrEP needs to evolve so that patients are not shamed or stigmatized by HCWs/policy makers for not using condoms if they feel adequately protected from HIV by adhering to PrEP
 - PrEP use needs to be re-framed as a positive and responsible option to remain HIV negative and that potential PrEP users are seen as taking control of their sexual health
- ***Chemsex users should be a priority population for PrEP***
 - 40% of participants used substances in the sexualized context (engaged in chemsex), mostly crystal meth with increasing use of GHB over time
 - Despite this, chemsex use did not appear to impact on overall PrEP adherence

Lessons Learnt (2)


- ***The preferred and most accessible sites for accessing PrEP (if all other factors were equivalent) was either the private clinic or the community based clinic.***
 - HIV treatment clinics offering PrEP in the hospital setting may be early adopters in providing PrEP but in the long term, PrEP provision is best delivered in key population clinics or private clinics which are already being accessed by key populations.
 - Task shifting to trained nurses or empowered members of key populations should be considered as part of de-medicalization of PrEP service delivery models.



Lessons Learnt (3)

- ***PrEP is an opportunity for STI control and prevention***
 - There was a **high prevalence of baseline STIs** which **preceded the initiation of PrEP**, most of which were **asymptomatic**, re-enforcing that we are reaching those at higher risk of HIV/STIs and emphasizing the importance of regular screening of extra-genital STIs and syphilis within MSM irrespective of symptoms
- ***National Guidelines need to be updated to include on-demand PrEP***
 - Although most patients agreed to take daily PrEP as part of the study, there was an increasing number of participants who had less frequent sex who expressed an interest to take on-demand PrEP
- ***PrEP Stigma was not assessed formally in this study*** but this should be looked into future implementation considerations and how this can impact on access to PrEP services

Emerging PrEP Service Delivery Models



- Primary Care (Klinik kesihatan) (5)
- ID Clinics (4)
- Community Based Organizations (CBO) (2)
- Private sector (20 private clinics, mostly private GP clinics)
- Demonstration projects (1)


Mainly urban areas in Malaysia

Providing PrEP to < 2000 patients

Considerations for scale up of PrEP

Malaysian Guidelines

Updated 2017



2 new
chapters

TABLE OF CONTENTS

Chapter 12	Management of Hepatitis C and HIV Co-Infection	63
12.1	Introduction	
12.2	Effects of HCV/HIV co-infection	
12.3	Effects of Antiretrovirals on HCV infection	
12.4	Pretreatment assessment	
12.5	Treatment Recommendation for HCV/HIV co-infection	
Chapter 13	ART among Serodiscordant Couples	66
Chapter 14	Antiretroviral Therapy for Illicit Drug Users	67
14.1	Introduction	
14.2	HIV Treatment among Illicit Drug Users / IDUs	
14.3	Drug interactions	
Chapter 15	Postexposure Prophylaxis (PEP) for HIV Infection Following Occupational Exposures	71
15.1	Introduction	
15.2	Risk for Occupational Transmission of HIV to HCWs	
15.3	Exposures for Which PEP is Indicated	
15.4	Immediate management	
15.5	PEP Recommendation when exposed to a Person of Unknown Status or to an unknown Source	
15.6	Which ARV drug regime to use?	
15.7	Timing of Initiation of PEP	
15.8	Duration of PEP	
15.9	Recommended Follow-Up of HCWs	
Chapter 16	Non Occupational Post Exposure Prophylaxis	75
16.1	Introduction	
16.2	Initial Assessment for nPEP	
16.3	Baseline HIV testing for the exposed patient	
16.4	Behavioural Intervention and Risk-Reduction Counselling	
16.5	Timing of nPEP	
16.6	Recommended Regimes	
Chapter 17	Pre Exposure Prophylaxis	83
17.1	Introduction	
17.2	Eligibility for PrEP	
17.3	The sexual partner of someone who is not on suppressive ART	
17.4	Prescribing PrEP	
17.5	Pre-PrEP Counselling & Assessment	
17.6	Laboratory evaluation	
17.7	Post-PrEP Follow-Up	
17.8	Management of special situations	

HIV Connect: Comprehensive training for GPs

- In collaboration with MMA, AFPM & MAF
- Modular training (9 modules)
 - Online modules (Phase 1)
 - Face-face training/workshops (Phase 2)
 - Clinical attachments (Phase 3)
- On completion
 - Certificates, CPD points

75% of GPs are from Klang Valley

35% are private GPs

1200 have enrolled. 457 have completed online modules, 78 have attended workshop



HIV CONNECT
ONLINE HIV TRAINING PROGRAMME
FOR PRIMARY CARE PHYSICIANS

MODULAR TRAINING
x 9 ONLINE MODULES

SECTION A	SECTION B	SECTION C
Basics of HIV/AIDS	PEP and PEP	Overview of STIs

BENEFITS OF TRAINING

1. Be at the forefront of HIV care in Malaysia. Stay updated on the latest HIV prevention, diagnosis, treatment, and care options.
2. Provide long-term care for patients with HIV within your own clinical practice.
3. Prescribe and dispense pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) to patients at high risk for HIV.
4. Get the latest management of sexually transmitted infections (STIs).

UPON COMPLETION YOU WILL GAIN

- Certificate

INTERESTED PHYSICIANS STAND TO GAIN

- Face-to-Face Training
- Clinical Attachments
- Community Partnership with Malaysian AIDS Council and Malaysian AIDS Foundation

REGISTER NOW @
HIVconnect.mashm.net

DISCLAIMER
Only for registered medical practitioners with valid MMA membership.

CONTACT
MASHM: mashm.malaysia@gmail.com
Malaysian AIDS Foundation: 03-4247-4312 | HIVconnect@maf.org.my



National Directory of PrEP Providers

- Increasing trend of users from age group 18-24 years
- An increase in users from Indonesia after integration of Malay language in My PrEP Locator
- Majority of the users accessed My PrEP Locator via mobile device.




The poster features the title "MyPrEP LOCATOR" in large white letters on a dark grey background. Below the title is the website "myprelocator.com" with a small icon. The background image shows hands holding a blue pill. Logos for "ceria", "mashm" (Malaysian Society for HIV Medicine), and other organizations are in the top right corner.

 AIM To create a national database of PrEP-providing clinics/hospitals to allow for patients to have access to a unified, vetted source of PrEP providers in an easily accessible database.	 TARGET PROVIDER Private and government clinic/hospital in Malaysia.	
 REQUIREMENT At least one registered medical doctor in charge in the clinic/hospital has completed PrEP module in HIV connect @ hivconnect.mashm.net	 BENEFIT FOR SERVICE PROVIDER 1 Streamline PrEP service in your clinic 2 Get discovered more 3 Strengthen your clinic reputation	
 STEPS FOR REGISTRATIONS		
 Complete PrEP module @ hivconnect.mashm.net	 Fill up the form at "Add Provider" @ myprelocator.com /add-provider	 Wait for approval within 2 weeks

Sponsored by

2nd National Consultation on PrEP

Recommendations



- The purpose of PrEP must remain on reducing HIV incidence, **and concerns of risk compensation need to be addressed with all stakeholders.**
- For PrEP to achieve large-scale coverage to impact HIV incidence, **greater collaboration, engagement, and sensitization is necessary within the Ministry of Health on PrEP-related policies and guidance for all key populations.**
- Cost of PrEP is no longer a barrier as low-cost generic ARVs are available, yet the **lack of information on the cost of PrEP is a barrier**, as many potential clients perceive PrEP as a costly drug
- **Community advocacy and leadership should drive PrEP access.**
- **Clinics led by key populations represent the most accessible service delivery model**, however regulatory and policy change will be required for this to be implemented and sustained outside research.

We need to simplify the way we deliver PrEP Post-COVID

Differentiated **PrEP** service delivery

	PrEP Screening, initiation and early follow-up (0-3 months)			PrEP continuation (+3 months)
	Screening	PrEP initiation visit	Initial follow-up	Routine clinical follow-up
WHEN <i>Service frequency</i>	Same-day		Months 1, 3	Every 3 months/ 6 months
WHERE <i>Service location</i>	KP-led clinics Mobile clinics		KP-led clinics	KP-led clinics/ Telehealth
WHO <i>Service provider</i>	KP lay providers dispense PrEP (which is prescribed remotely by doctors)		KP lay providers	KP lay providers
WHAT <i>Service package</i>	- Same-day HIV/syphilis testing - Cr, HBsAg (results come later) - PrEP counseling		- HIV testing - PrEP counseling	Xpress, self-sampling/testing for HIV/STIs - Syphilis testing and Cr (every 6 months) - PrEP/effective use counseling

USAID LINKAGES project, September 2020.

Next Steps.....

- Increasing community-led PrEP services
 - Collaboration with FRHAM (Family Planning)
- Formation of National PrEP Task Force
- Strengthening linkage of PrEP providers, HIV Connect, My PrEP locator, DHSKP & HIV ST interventions
 - Use of PrEP navigators
- Increase in PrEP demand generation activities
 - use of community PrEP ambassadors/influencers
 - Positive re- branding of PrEP
- Increase functionality of my PrEP Locator
- Centralized & competitive PrEP procurement negotiations with Pharma
- Strengthen government commitment & setting of national PrEP targets

Summary

- There is an urgent need to prioritize PrEP as an HIV prevention tool alongside increased HIV testing and treatment as prevention in Malaysia
- We have made some progress but it has been very slow
- PrEP service provision should be linked to HIV testing services
- Concerns of risk compensation need to be addressed with all stakeholders
 - PrEP use needs to be re-framed as a positive and responsible option to remain HIV negative
- Community based & Key population led/involved clinics are the most accessible service delivery model but will require regulatory and policy changes to make it sustainable

Summary

- Community empowerment, advocacy and leadership must drive PrEP access
- Future work should look at:
 - implementation research in TGs, sex workers and PWID
 - Novel and accessible PrEP service delivery models (e.g. on-line models)
 - M & E PrEP indicators and PrEP cascade

Acknowledgements

- All study participants
- Dr. Frits Van Griensven
- Dr. Ying-Ru Lo, WHO
- Mohd Akbar Ab Halim
- Dr Jeffrey Wickersham
- Dr Sazali Basri
- Meng Li Chong
- Nishaan Raman
- Raymond Tai
- Frederick Pour
- Dr Andrew Yap

